Duke University Medical Center
Durham, North Carolina, 27710, United States
NCT Number: NCT01385215
The purpose of this study is to determine the safety and effectiveness of the influenza vaccine when administered nasally and intra-muscular (a "shot" of medicine given into a muscle). The investigators will measure the systemic (through out the body) and mucosal immune responses (how your body recognizes and defends itself against bacteria) to nasally administered influenza vaccine, and determine if nasal immunization results in immunity (your body's ability to avoid infections) within multiple mucosal compartments (ocular (eye), oral and reproductive), in comparison with intramuscular administration and placebo (inactive substance given in the same form as the active drug).
Looking for future studies?
Notify Me18 year–50 year
All sexes
Interventional
Early Phase 1
Durham, North Carolina, 27710, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
0.5 ml/15 micrograms
Time frame: Baseline to Day 28
Assessments will include hemagglutination inhibition and antibody isotypes determination.
Time frame: Baseline to Day 28
Time frame: Baseline to Day 28
John Sundy
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06970964
Athletic Performance, Behavior
São Paulo, Brazil
View Trial DetailsNCT05794412
COVID-19, Coronaviridae Infections
Geneva, Switzerland
View Trial DetailsNCT07085611
Animal Diseases, COVID-19
Orléans, France
View Trial DetailsNCT06902194
Infections, Mucosal Immunity
Cape Town, Western Cape, South Africa
View Trial Details